Drug Profile
VRC-HIVADV027-00-VP
Alternative Names: Ad35HIV-EnvA; HIV adenovector serotype Ad35 vaccine - GenVec/NIAID; rAd35-EnvA vaccine; VRC-rAd35 HIV vaccine - GenVecLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator GenVec; National Institute of Allergy and Infectious Diseases
- Developer National Institute of Allergy and Infectious Diseases
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy, Prevention, In volunteers) in Kenya (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy, Prevention, In volunteers) in Rwanda (IM, Injection)
- 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-1-infections(Combination therapy, Prevention, In volunteers) in South Africa (IM, Injection)